Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Pulse Update
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease
-
Media Release
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in… -
Media Release
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year… -
Biologist to Head-hunter
I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.
-
Addressing unmet needs for inherited neuromuscular diseases
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
-
Key Release
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to… -
Media Release
Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration… -
Featured News
Official partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
My Journey to Novartis: Finding my Purpose and Passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely different from what I was used to. But what sealed the deal for me was a conversation with my then manager who told me that the purpose I would feel and impact I would have would be unique. And she was right.
-
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Media Release
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
-
Media Release
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in… -
Media Release
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year… -
Key Release
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to… -
Media Release
Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration… -
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
Key Release
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +10% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +20% (kWk, +17% USD)Das Umsatzwachstum… -
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Media Release
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of… -
Media Release
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and… -
Media Release
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant… -
Media Release
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1More than 80… -
Key Release
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
-
Key Release
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to… -
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
Key Release
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +10% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +20% (kWk, +17% USD)Das Umsatzwachstum… -
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Key Release
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4… -
Key Release
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,… -
Key Release
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Key Release
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
Annonce événementielle au sens de l’art. 53 RCRésultats du deuxième trimestre (T2)Chiffre d’affaires net en hausse de +11% (tcc1, +9% USD) et du résultat opérationnel core, de +19% (tcc, +17% USD) La… -
Key Release
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +19% (kWk, +17% USD) Das Umsatzwachstum… -
Key Release
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum including Entresto… -
Key Release
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Ad hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by… -
Key Release
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
Annonce événementielle au sens de l’art. 53 RCExercice complet (activités poursuivies2)Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du…
-
Featured News
Official partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
Featured News
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.
-
Featured News
Our next era
Novartis poised to expand impact on human health as it begins next era.
-
Featured News
Novartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
Featured News
Creating positive social change through volunteering
Over 1 billion people volunteer worldwide, sharing their skills and experience, providing support within their communities, and offering emergency assistance to those in need. On International Volunteer Day (December 5), we join forces with the UN to recognize the tireless work of all volunteers and the contributions that they make.
-
Featured News
World Sight Day 2022: Raising awareness on the importance of eye health
Through the Avoidable Blindness Program, Novartis is working with partners to strengthen eye health in sub-Saharan Africa.
-
Featured News
Novartis Hematology: Working to help ensure patients are getting the access they need
Developing treatments for blood cancers and serious blood disorders is important, but it is only part of the equation. We also need to help ensure those who may need our therapies can get them.
-
Featured News
From the Heart
-
Featured News
Novartis Co-Creating Impact Summit 2021
Over 1,800 delegates came together at the annual Co-Creating Impact Summit to explore how understanding ‘impact’ is a crucial step in ensuring business makes a positive contribution to the world.
-
Featured News
Raising awareness of prostate cancer during Movember
Despite advancements in care, prostate cancer is one of the most frequently diagnosed cancers around the world. This Movember, we’re focused on raising awareness of prostate cancer.
-
Featured News
Sound Up for Lung Cancer
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.
-
Featured News
World Sight Day 2021
Novartis is working with partners around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care.
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement
Novartis provides support for Moroccan earthquake victims
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Statement
Novartis statement on filing of Inflation Reduction Act lawsuit
-
Statement
Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Statement
European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
-
Statement
CHMP recommends revoking the conditional marketing authorization for Adakveo® (crizanlizumab)
-
Statement
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
-
Statement
Novartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs
-
Pulse Update
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease
-
Pulse Update
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
-
Pulse Update
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
-
Pulse Update
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
-
Pulse Update
Novartis appoints Sloan Simpson as Global Head of Investor Relations
-
Pulse Update
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
-
Pulse Update
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®
-
Pulse Update
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
-
Pulse Update
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
-
Pulse Update
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
-
Pulse Update
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Pulse Update
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Biologist to Head-hunter
I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.
-
Addressing unmet needs for inherited neuromuscular diseases
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
-
My Journey to Novartis: Finding my Purpose and Passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely different from what I was used to. But what sealed the deal for me was a conversation with my then manager who told me that the purpose I would feel and impact I would have would be unique. And she was right.
-
Negative impact of the IRA on patient access to innovative treatments
At Novartis, we are constantly pushing the limits of science to develop and deliver transformative medicines that fight disease and help people live life on their terms.
-
Every number has a story – my journey to Novartis as a Refugee
The current refugee crisis is one of the world's greatest humanitarian challenges. Svitlana shares her story of her journey to Novartis and how her work as part of the Giving and Volunteering team is opening the doors to refugees and other marginalized groups and allowing our people to make a difference by helping those who are most vulnerable.
-
Is Diversity, Equity and Inclusion (DEI) really that important?
We think so and here are just some of the reasons why: we believe our workplace should reflect today’s emerging workforce; every culture needs diversity to thrive; and it supports fair treatment and opportunities for all our people.
-
A legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis
From curiosity about life on Earth to transformative therapies at Novartis. Michelle L Krishnan, Executive Director, MD PhD.
-
From black holes to AI driven drug discovery – collaboration wins the day
Dr Bülent Kızıltan, Global Head of AI & Computational Sciences
-
Drug delivery, service delivery, and the future of cancer care
State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.
-
Listening to the CML patient community
Improving the patient experience and removing potential barriers to clinical trial participation
-
How collaboration can enhance your science career
Kumar Veerapen, Senior Expert I Data Science
Novartis Financial Results – Q3 2024
Novartis announced the company’s financial results for the third quarter of 2024.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.